A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer

NCT05830240 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Cancer
Esophageal Cancer
Otorhinolaryngologic Neoplasms
Ear Cancer
Nose Cancer
Laryngeal Cancer
Pharyngeal Cancer

Interventions

DRUG: Recombinant oncolytic herpes simplex virus type 1 (R130)

Sponsor

Shanghai Yunying Medical Technology

Collaborators

[object Object]